Dasatinib is a tyrosine kinase inhibitor used for treatment of some specific types of leukaemia.The development of pleural effusion is a known adverse effect of dasatinib and chylothorax is exceptional.No case has been reported c6097b1028 beyond 5 years of treatment and extensive search for an alternative diagnosis is currently suggested in such scenario.
The underlying bob the boxcutter mechanism is not currently clear.We describe a woman on dasatinib treatment for more than 10 years who developed chylothorax.Drug withdrawal resolved the chylous pleural effusion.
We were able to find 14 additional cases of dasatinib-related chylothorax reported up until now.